

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

January 24, 2025

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051.

Symbol: RPGLIFE

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Scrip code: 532983

Dear Sir/Madam,

Sub: Integrated Filing (Financial) for the guarter ended December 31, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter ended December 31, 2024.

Kindly take the above on record.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

Rajesh Shirambekar Head – Legal & Company Secretary SRBC& COLLP Chartered Accountants

12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Mumbai - 400 028, India

Tel: +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors RPG Life Sciences Limited

- 1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended December 31, 2024 and year to date from April 1, 2024 to December 31, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



SRBC&COLLP

Chartered Accountants

5. We draw attention to Note 5 of the financial results, which describes the potential effects arising on account of fire in a production facility of the Company subsequent to the quarter ended December 31, 2024. Our conclusion is not modified in respect of this matter.

For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003

Juena

per Aruna Kumaraswamy Partner Membership No.: 219350 UDIN: 252193508MLZZW 3857 Place: Mumbai Date: January 24, 2025





RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-269757100 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024

					2	(Rs. in Lakhs)
	Quarter ended			Nine months ended		Year ended
Particulars	31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Demonsterne	17 271	17,221	15,370	51,034	45;506	58,205
1 Revenue from Operations	17,271 331	17,221	13,370	762	45,500	721
2 Other Income	17,602	194	15,562	51,796	46,062	58,926
3 Total Income (1+2)	17,002	17,415	15,502	51,790	40,002	50,720
4 Expenses						· · · · ·
(a) Cost of Materials Consumed	3,019	2,081	2,485	8,337	9,262	12,065
(b) Purchases of Stock-in-Trade	2,270	2,633	1,649	7,392	4,626	6,118
(c) Changes in Inventories of Finished Goods, Work-in-Progress		1				
and Stock-in-Trade	322	703	683	800	421	270
(d) Employee Benefits Expense	2,871	3,309	3,369	9,454	10,007	13,215
(e) Finance Costs	12	17	14	44	31	45
(f) Depreciation and Amortisation Expense	546	531	414	1,606	1,258	1,707
(g) Other Expenses	3,873	3,902	3,394	11,635	10,447	13,722
Total Expenses	12,913	13,176	12,008	39,268	36,052	47,142
	,	,	, i i			
5 Profit before exceptional items and tax (3-4)	4,689	4,239	3,554	12,528	10,010	11,784
6 Exceptional items (Refer Note 3)	-	(2,730)	-	(2,730)	-	-
7 Profit before tax	4,689	1,509	3,554	9,798	10,010	11,784
8 Income tax expenses	1 100	1.079	050	2 2 2 1	2,709	3,254
a. Current Tax b. Deferred Tax	1,192	1,078 11	950 (42)	3,221 (12)	(141)	(236)
Total tax expenses	1,196	1,089	908	3,209	2,568	3,018
1 otar tax expenses	1,190	1,005	200	5,207	2,500	5,010
9 Profit for the period (7-8)	3,493	420	2,646	6,589	7,442	8,766
 10 Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified to 	2	3	2	7	7	(75)
Profit or Loss	(1)	(1)	(1)	(3)	(3)	19
Other Comprehensive Income Net of Tax	1	2	1	4	4	(56)
11 Total Comprehensive Income for the period (9+10)	3,494	422	2,647	6,593	7,446	8,710
•	5,174		2,017	0,000	,	5,710
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
13 Other Equity						36,162
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				×		
(a) Basic (in Rs.)	21.12	2.54	16.00	39.84	45.00	53.01
(b) Diluted (in Rs.)	21.12	2.54	16.00	39.84	45.00	53.01
	21.12	2.34	10.00	57.04	+5.00	1 35.01

SIGNED FOR IDENTIFICATION BY S R B C & CO LLP MUMBAI





RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-269757100 Email: info@rpglifesciences.com www.rpglifesciences.com CIN : L24232MH2007PLC169354

Notes:

- 1. The above unaudited financial results have been reviewed and recommended by the Audit Committee at its meeting held on January 23, 2025 and have been approved by the Board of Directors at its meetings held on January 24, 2025.
- 2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- 3. Exceptional items for the period ended December 31, 2024 represents transfer charges of INR 2,730 lakhs paid by the Company, pursuant to the receipt of the order dated September 12, 2024 from Maharashtra Industrial Development Corporation (MIDC), Navi Mumbai in response to the Company's application under amnesty scheme as per Government Resolution (GR) dated July 26, 2024 (as amended) in respect of levy of transfer charges towards assignment of portion of leasehold rights made in earlier periods under the Urban Land (Ceiling and Regulation) Act, 1976.
- 4. The Company has executed a binding agreement dated September 13, 2024 with M/s. KRSNA Dynasty, an unrelated party, for assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai for a consideration of INR 14,563 lakhs plus applicable GST (subject to applicable income tax deducted at source). The transaction is subject to satisfactory completion of the Conditions Precedent in the agreement and obtaining necessary approvals which are currently underway and the same is expected to be completed in Q4 FY25.
- 5. On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Company located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai 400703, Maharashtra. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in the incidence. The said incident has an impact on part of the Building, Plant & Machinery, inventories and other assets of the said block. The Company is in the process of estimating the extent of damage caused and loss arising on account of such damage. The Company believes that all the assets in the said plant are adequately covered under insurance, necessary intimation to insurance company has already been given and the Company expects to receive first tranche of interim payment soon. The Company is fully engaged in restricting the business loss from such interruption to the lowest possible extent. Since, this is a non-adjusting subsequent event, no adjustment has been made in the financial results for the quarter and period ended December 31, 2024.



MUMBAI 400030

For RPG Life Sciences Limited

Yugal Sikri Managing Director Mumbai, January 24, 2025





 RPG LIFE SCIENCES LIMITED

 Regd. Off.: RPG House

 463, Dr. Annie Besant Road

 Worli, Mumbai 400030, India

 Tel: +91-22-24981650 / 66606375

 Fax: +91-22-24970127

 Email: info@rpglifesciences.com

 www.rpglifesciences.com

 CIN : L24232MH2007PLC169354

- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. – Not Applicable.
- C. **FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES** Not Applicable.

Sr. No.	Particulars	
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
А	Total amount outstanding as on date	0
В	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
А	Total amount outstanding as on date	0
В	Of the total amount outstanding, amount of default as on date	0
3.	Total financial indebtedness of the listed entity including short- term and long-term debt	0

- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half yearly filings i.e., 2nd and 4th quarter) Not Applicable.
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) Not Applicable.

An ��RPG Company